Member Info for alphabravo321

I attended the FAST meeting in Dublin this evening, CF hosted the meeting with presentations from AMRYT CEO and CFO, both went into great detail on how the plan was put together and how it all came about. CEO Joe Wiley presented for approx 40 mins on the current products and potential future lines including the potential for near term licensing deals on existing and currently in development products. By far the star of the show is Episalvan and its potential use in the sure of certain types of wounds. They explained the approvals they have to date and the timelines for further clinical trials. The level of detail, organisation and the ease with which they discussed the fairly complex subject matter was impressive along with calibre of the team particularly the BOD. The presentation will be on the FAST web, it is very interesting reading particularly the market cap comparisons of similar companies with drugs at various stages of regulatory approval. I was happy before I went in, I am a lot happier now.My personal view is that they see several significant events in the 3-15 month range post RTO.

Cathal presenting at the Proactive Investor Forum on FAST on the 7th of April in London

The Company will initially focus on opportunities located in Europe but will also consider businesses in other geographical regions. The Directors believe that they have a broad collective range of sources of potential opportunities but also intend to appoint one or more additional directors with the relevant industry experience, subject to the Investing Policy being approved by Shareholders. The Directors will identify and assess potential investment targets and, where they believe further investigation is required, intend to appoint appropriately qualified external professionals to assist. The initial objective of the Directors is to create incremental capital appreciation and any revenue generated by the Company will be applied to further the Investing Policy or will be used in the day to day management of the Company. Dividends may be declared at some future date depending on the financial position of the Company and the availability of distributable accounting profits. The Directors intend that the Company takes an equity interest in a proposed investment which is likely to be a majority position to 100 per cent. ownership. The Company's financial resources are likely to be invested in potentially one or more investments in a single transaction which will be deemed to be a reverse takeover pursuant to Rule 14 of the AIM Rules and ESM Rules, in which case the approval of the Shareholders will be required. Proposed investments may be made in quoted or unquoted securities in companies or partnerships at any stage of development.